MRC5 cells engineered to express ACE2 serve as a model system for the discovery of antivirals targeting SARS-CoV-2

• Published in: Scientific reports Vol. 11; no. 1; pp. 5376 - 9
• Main Authors: Uemura, Kentaro, Sasaki, Michihito, Sanaki, Takao, Toba, Shinsuke, Takahashi, Yoshimasa, Orba, Yasuko, Hall, William W., Maenaka, Katsumi, Sawa, Hirofumi, Sato, Akihiko
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 08.03.2021; Nature Publishing Group; Nature Portfolio
• Subjects: 631/326; 631/326/596; 631/326/596/1296; 631/326/596/4130; ACE2; Angiotensin; Angiotensin-converting enzyme 2; Angiotensin-Converting Enzyme 2 - metabolism; Animals; Antiviral agents; Antiviral Agents - pharmacology; Antiviral Agents - therapeutic use; Antiviral drugs; Cell Engineering; Cell Line; Coronaviruses; COVID-19; COVID-19 - drug therapy; Drug development; Drug Discovery; Humanities and Social Sciences; Humans; Infectivity; Models, Biological; multidisciplinary; Pandemics; Peptidyl-dipeptidase A; Replication; Ribonucleic acid; RNA; RNA viruses; SARS-CoV-2 - drug effects; SARS-CoV-2 - physiology; Science; Science (multidisciplinary); Severe acute respiratory syndrome coronavirus 2; Vaccine development; Vero cells; Viral Proteins - biosynthesis; Virus Replication - drug effects

Although the spread of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has resulted in a worldwide pandemic, there are currently no virus-specific drugs that are fully effective against SARS-CoV-2. Only a limited number of human-derived cells are capable of supporting SARS-CoV-2 replica...